KRAS mutations are found in over 90% of conventional pancreatic adenocarcinomas, indicating that the KRAS pathway is heavily associated with invasion, whereas GNAS mutations are less commonly identified [17,21]. Here, GNAS is linked to pancreatic adenocarcinoma.